NOVOZYMES -B-
NOVOZYMES -B- operates in Diversified Metals & Mining.
NOVOZYMES -B- (NZM2) - Total Assets
Latest total assets as of December 2023: €28.39 Billion EUR
Based on the latest financial reports, NOVOZYMES -B- (NZM2) holds total assets worth €28.39 Billion EUR as of December 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
NOVOZYMES -B- - Total Assets Trend (2016–2023)
This chart illustrates how NOVOZYMES -B-’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
NOVOZYMES -B- - Asset Composition Analysis
Current Asset Composition (December 2023)
NOVOZYMES -B-'s total assets of €28.39 Billion consist of 33.3% current assets and 66.7% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 3.9% |
| Accounts Receivable | €3.70 Billion | 13.0% |
| Inventory | €3.63 Billion | 12.8% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €2.56 Billion | 9.0% |
| Goodwill | €1.98 Billion | 7.0% |
Asset Composition Trend (2016–2023)
This chart illustrates how NOVOZYMES -B-'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NOVOZYMES -B-'s current assets represent 33.3% of total assets in 2023, a decrease from 34.3% in 2016.
- Cash Position: Cash and equivalents constituted 3.9% of total assets in 2023, down from 4.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 15.0% of total assets, an increase from 14.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 13.0% of total assets.
NOVOZYMES -B- Competitors by Total Assets
Key competitors of NOVOZYMES -B- based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MANHATTAN ASSOC
BE:MHT
|
Germany | €698.14 Million |
|
TV BROADCAST
MU:TBCN
|
Germany | €6.25 Billion |
|
FIRST CITIZENS BC A
BE:FC6A
|
Germany | €220.57 Billion |
|
COSTCO WHSL
MU:CTO
|
Germany | €69.83 Billion |
|
GOLDMAN SACHS GROUP - Dusseldorf Stock Exchang
DU:GOS
|
Germany | €1.73 Trillion |
|
BURCKHARDT COMPRE N
MU:B5H
|
Germany | €1.07 Billion |
|
Public Service Company of New Mexico PFD 4.58%
PINK:PNMXO
|
USA | $886.19 Million |
|
2H0
F:2H0
|
Germany | €15.27 Million |
NOVOZYMES -B- - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - NOVOZYMES -B- generates 0.63x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, NOVOZYMES -B- generates $ 10.65 in net profit.
NOVOZYMES -B- - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.30 | 1.33 | 1.22 |
| Quick Ratio | 0.80 | 0.78 | 0.71 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €2.20 Billion | € 2.28 Billion | € 1.21 Billion |
NOVOZYMES -B- - Advanced Valuation Insights
This section examines the relationship between NOVOZYMES -B-'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 1.5% |
| Total Assets | €28.39 Billion |
| Market Capitalization | $530.78K USD |
Valuation Analysis
Below Book Valuation: The market values NOVOZYMES -B-'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: NOVOZYMES -B-'s assets grew by 1.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for NOVOZYMES -B- (2016–2023)
The table below shows the annual total assets of NOVOZYMES -B- from 2016 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | €28.39 Billion | +1.46% |
| 2022-12-31 | €27.98 Billion | +12.99% |
| 2021-12-31 | €24.77 Billion | +20.76% |
| 2020-12-31 | €20.51 Billion | +0.36% |
| 2019-12-31 | €20.44 Billion | +3.76% |
| 2018-12-31 | €19.70 Billion | +7.21% |
| 2017-12-31 | €18.37 Billion | -1.53% |
| 2016-12-31 | €18.66 Billion | -- |